{
    "nct_id": "NCT06782932",
    "official_title": "A Pilot Study Comparing Neoadjuvant and Adjuvant GVAX vs a Mutated KRAS Peptide Vaccine Given With Anti-PD-1 and Anti-CD137 for the Treatment of Surgically Resectable Pancreatic Adenocarcinoma",
    "inclusion_criteria": "* Have a newly diagnosed, biopsy-proven adenocarcinoma of the pancreas.\n* Tumor must be deemed resectable by the study team\n* Patient's acceptance to have a tumor biopsy.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1.\n* Patients must have adequate organ and marrow function defined by study-specified laboratory tests and procedures.\n* Women of childbearing potential (WOCBP) must have a negative serum pregnancy test.\n* For both Women and Men, must use acceptable form of birth control while on study.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Received any anti-pancreatic cancer therapy (symptomatic therapies are allowed), or any prior anti-cancer immunotherapy.\n* Diagnosed with another cancer whose natural history or treatment could interfere with safety or efficacy assessments on this study.\n* Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness/social situations that would limit compliance with study requirements.\n* Active autoimmune disease.\n* Systemic steroid therapy (> 10mg daily prednisone equivalent) or immunosuppressive therapy within 14 days of first dose of study drug administration.\n* Active infection requiring systemic therapy.\n* Known history of human immunodeficiency virus (HIV).\n* Active or chronic hepatitis B or hepatitis C.\n* Known active tuberculosis.\n* History of interstitial lung disease, non-infectious pneumonitis or uncontrolled lung diseases including pulmonary fibrosis, acute lung diseases, chronic obstructive pulmonary disease (COPD), asthma requiring medication, etc.\n* Prior allogeneic stem cell transplantation or organ transplantation.\n* Any major surgical procedure requiring general anesthesia ≤ 28 days before first dose of study drug.\n* Received a live vaccine ≤ 28 days before first dose of study drug.\n* History of severe hypersensitivity reaction to any monoclonal antibody\n* Concurrent participation in another therapeutic clinical study\n* Pregnant or breastfeeding",
    "miscellaneous_criteria": ""
}